Joel Scherer

1.1k total citations
7 papers, 759 citations indexed

About

Joel Scherer is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Joel Scherer has authored 7 papers receiving a total of 759 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cardiology and Cardiovascular Medicine, 5 papers in Surgery and 3 papers in Internal Medicine. Recurrent topics in Joel Scherer's work include Acute Myocardial Infarction Research (6 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers) and Coronary Interventions and Diagnostics (3 papers). Joel Scherer is often cited by papers focused on Acute Myocardial Infarction Research (6 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers) and Coronary Interventions and Diagnostics (3 papers). Joel Scherer collaborates with scholars based in United States, Belgium and Canada. Joel Scherer's co-authors include Robert P. Giugliano, Eugene Braunwald, Frans Van de Werf, Elliott M. Antman, Carolyn H. McCabe, Keaven M. Anderson, C. Michael Gibson, Ron van der Wieken, Neal S. Kleiman and Ian Menown and has published in prestigious journals such as Circulation, American Heart Journal and Catheterization and Cardiovascular Interventions.

In The Last Decade

Joel Scherer

7 papers receiving 713 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joel Scherer United States	6	654	398	262	163	98	7	759
Barry George United States	7	732 1.1×	626 1.6×	322 1.2×	155 1.0×	91 0.9×	14	928
H. Köstering Germany	7	787 1.2×	467 1.2×	566 2.2×	80 0.5×	43 0.4×	17	988
Cihan Dündar Türkiye	16	553 0.8×	191 0.5×	196 0.7×	38 0.2×	67 0.7×	46	659
Claude Vaislic France	12	326 0.5×	462 1.2×	64 0.2×	106 0.7×	41 0.4×	27	732
Tomoki Ohara Japan	13	375 0.6×	343 0.9×	286 1.1×	32 0.2×	40 0.4×	40	669
M Nobuyoshi Japan	11	715 1.1×	505 1.3×	355 1.4×	45 0.3×	124 1.3×	30	929
Cemil İzgi United Kingdom	14	508 0.8×	177 0.4×	169 0.6×	30 0.2×	105 1.1×	45	721
Marion Durand France	10	343 0.5×	138 0.3×	65 0.2×	154 0.9×	29 0.3×	39	513
Won Yu Kang South Korea	12	474 0.7×	348 0.9×	251 1.0×	60 0.4×	39 0.4×	36	685
Fernando Cura Argentina	9	421 0.6×	302 0.8×	206 0.8×	95 0.6×	16 0.2×	50	524

Countries citing papers authored by Joel Scherer

Since Specialization

Citations

This map shows the geographic impact of Joel Scherer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Scherer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Scherer more than expected).

Fields of papers citing papers by Joel Scherer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Scherer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Scherer. The network helps show where Joel Scherer may publish in the future.

Co-authorship network of co-authors of Joel Scherer

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Scherer. A scholar is included among the top collaborators of Joel Scherer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Scherer. Joel Scherer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Lage, Maureen J., Beth Barber, Patrick L. McCollam, Mohan Bala, & Joel Scherer. (2001). Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients. Catheterization and Cardiovascular Interventions. 53(3). 296–303. 7 indexed citations

2.

Lage, Maureen J., Beth Barber, Patrick L. McCollam, Mohan Bala, & Joel Scherer. (2001). Impact of abciximab versus tirofiban on hospital length of stay for PCI patients. Catheterization and Cardiovascular Interventions. 52(3). 298–305. 5 indexed citations

3.

Lemos, James A. de, Elliott M. Antman, C. Michael Gibson, et al.. (2000). Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial Infarction. Circulation. 101(3). 239–243. 189 indexed citations

4.

Coulter, Stephanie, Christopher P. Cannon, Kenneth A. Ault, et al.. (2000). High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction. Circulation. 101(23). 2690–2695. 53 indexed citations

5.

Fung, Anthony, Gerald Lorch, Patrick Cambier, et al.. (1999). Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. American Heart Journal. 138(4). 696–704. 13 indexed citations

6.

Antman, Elliott M., Robert P. Giugliano, C. Michael Gibson, et al.. (1999). Abciximab Facilitates the Rate and Extent of Thrombolysis. Circulation. 99(21). 2720–2732. 491 indexed citations

7.

Fleming, David A., et al.. (1981). Prazosin HC1 in Treating Hypertension Associated With Pheochromocytoma. Southern Medical Journal. 74(8). 1010–1011. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact